» Articles » PMID: 35575911

Risk Factors for Adverse Outcomes Following Haploidentical Hematopoietic Cell Transplantation with Posttransplant Cyclophosphamide: a Two-center Analysis

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for several malignant hematologic diseases and alternative donors, including haploidentical, play a significant role in HCT. Despite the increasing use of haplo-HCT with PTCy, some questions remain open. The objective of the present study was to investigate risk factors for adverse outcomes after haplo-HCT with PTCy. This is a retrospective study conducted at two Brazilian centers. A total of 103 patients with hematologic malignancies who underwent first allogeneic, haploidentical HCT with PTCy were included. Risk factors for death were age at transplant (HR = 1.03 for each year; p = 0.002) and high/very high disease risk index (DRI; HR = 2.77; p = 0.0007) and mother as the donor compared with other donors (HR = 3.53; p = 0.005). In multivariate analysis, PFS was significantly poorer for older patients (HR = 1.02; p = 0.006), high/very high DRI (HR = 2.39; p = 0.003), and mother as the donor compared with other donors (HR = 3.18; p = 0.006). Relapse rate was higher for high/very high DRI (HR = 4.01; p = 0.002) and mother as the donor compared with other donors (HR = 2.52; p = 0.05). NRM was higher for older patients (HR = 1.03 for each year; p = 0.03). Tacrolimus was a protective factor for grades II-IV aGVHD (HR = 0.46; p = 0.04) compared with cyclosporine. Peripheral blood (PBSC) was a risk factor for cGVHD (HR = 3.48; p = 0.006), while tacrolimus was protective (HR = 0.30; p = 0.009). Mother as the donor compared with other donors was also a risk factor for poorer OS, PFS, and relapse, suggesting that this combination should be avoided. Tacrolimus was protective for both grades II-IV aGVHD and cGVHD, suggesting that tacrolimus may be more effective than cyclosporine in preventing GVHD. PBSC was a risk factor for cGVHD without any impact on relapse. Prospective studies comparing tacrolimus with cyclosporine are awaited.

Citing Articles

HLA and Non-HLA Factors for Donor Selection in Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide GvHD Prophylaxis.

Shike H, Zhang A Cells. 2025; 13(24.

PMID: 39768158 PMC: 11674641. DOI: 10.3390/cells13242067.


Clinical relevance of feto-maternal microchimerism in (hematopoietic stem cell) transplantation.

Kruchen A, Fehse B, Muller I Semin Immunopathol. 2024; 47(1):4.

PMID: 39644358 PMC: 11625077. DOI: 10.1007/s00281-024-01028-3.


Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.

Nakamae H Front Immunol. 2024; 15:1403936.

PMID: 38903503 PMC: 11187280. DOI: 10.3389/fimmu.2024.1403936.

References
1.
Raiola A, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A . Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014; 20(10):1573-9. DOI: 10.1016/j.bbmt.2014.05.029. View

2.
OReilly R, Keever C, Kernan N, Brochstein J, Collins N, Flomenberg N . HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc. 1987; 19(6 Suppl 7):55-60. View

3.
Bethge W, Faul C, Bornhauser M, Stuhler G, Beelen D, Lang P . Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2007; 40(1):13-9. DOI: 10.1016/j.bcmd.2007.07.001. View

4.
Rizzieri D, Koh L, Long G, Gasparetto C, Sullivan K, Horwitz M . Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007; 25(6):690-7. DOI: 10.1200/JCO.2006.07.0953. View

5.
Luznik L, ODonnell P, Symons H, Chen A, Leffell M, Zahurak M . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6):641-50. PMC: 2633246. DOI: 10.1016/j.bbmt.2008.03.005. View